Sage Therapeutics Q2 EPS $(1.70) Misses $(1.66) Estimate, Sales $8.65M Miss $8.85M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics (NASDAQ:SAGE) reported Q2 earnings per share (EPS) of $(1.70), missing the analyst estimate of $(1.66) by 2.41%. Quarterly sales were $8.65 million, also missing the estimate of $8.85 million by 2.19%. Despite the misses, both EPS and sales showed significant improvement compared to the same period last year.
July 31, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sage Therapeutics reported Q2 EPS of $(1.70), missing the estimate of $(1.66) by 2.41%. Sales were $8.65 million, missing the estimate of $8.85 million by 2.19%. Despite the misses, both metrics showed significant year-over-year improvement.
The misses on both EPS and sales estimates are likely to have a negative short-term impact on the stock price. However, the significant year-over-year improvement in both metrics may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100